51
Jens Peter Gregersen: Decreasing potential iatrogenic risks associated with influenza vaccines. Amy Hessler, Otis Littlefield, Robert J Gorman, February 21, 2012: US08119337 (3 worldwide citation)

Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realized that the conditions used for influenza virus 5 cult ...


52
HOFFMAN ERICH, JIN HONG, LU BIN, DUKE GREG, KEMBLE GEORGE WILLIAM: SYSTEME MULTIPLASMIDE DE PRODUCTION DE VIRUS INFLUENZA, MULTI PLASMID SYSTEM FOR THE PRODUCTION OF INFLUENZA VIRUS. MEDIMMUNE VACCINES, MEDIMMUNE VACCINES, FETHERSTONHAUGH & CO, September 17, 2013: CA2482946 (3 worldwide citation)

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.


53
Minke Jules Maarten, Karaca Kemal, Yao Jiansheng: Canine influenza vaccines. Merial, Minke Jules Maarten, Karaca Kemal, Yao Jiansheng, JARECKI BLACK PHD JD Judy, March 1, 2007: WO/2007/024947 (3 worldwide citation)

The present invention encompasses influenza vaccines, in particular canine influenza vaccines. The vaccine may be a recombinant poxvirus vaccine or an inactivated vaccine. The invention also encompasses recombinant poxvirus vectors encoding and expressing influenza antigens, epitopes or immunogens w ...


54
Couture Manon, Vézina Louis Philippe, Landry Nathalie: New influenza virus immunizing epitope. Medicago, Couture Manon, Vézina Louis Philippe, Landry Nathalie, Ogilvy Renault Sencrl, January 21, 2010: WO/2010/006452 (3 worldwide citation)

A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of a novel influenza HA protein in plants and its purification The invention is also directed towards a VLP comprising influenza HA protein and plants li ...


55
D Aoust Marc André, Couture Manon, Ors Frédéric, Trépanier Sonia, Lavoie Pierre Olivier, Dargis Michèle, Vézina Louis Philippe, Landry Nathalie: (vlps) Produced in transgenic plants expressing hemagglutinin. Medicago, D Aoust Marc André, Couture Manon, Ors Frédéric, Trépanier Sonia, Lavoie Pierre Olivier, Dargis Michèle, Vézina Louis Philippe, Landry Nathalie, SECHLEY Konrad A, June 25, 2009: WO/2009/076778 (3 worldwide citation)

A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA pro ...


56
Webb Steven Robert, Henry Matthew J: Vaccine for avian influenza and methods of use. Dow Agrosciences, Webb Steven Robert, Henry Matthew J, EISENSCHENK Frank C, May 22, 2008: WO/2008/060669 (3 worldwide citation)

The subject invention pertains to influenza vaccines and particularly avian influenza vaccines (AIV). The invention includes methods for preparing transgenic plant cells to express know HAl polypeptides having specified homologies that are used to prepare vaccine compositions and methods for inducin ...


57
Hoffmann Erich, Lipatov Aleksandr S, Webster Robert G, Webby Richard J, Govorkova Elena A: Modified influenza virus for monitoring and improving vaccine efficiency. St Jude Children S Research Hospital, Hoffmann Erich, Lipatov Aleksandr S, Webster Robert G, Webby Richard J, Govorkova Elena A, LUDWIG S Peter, February 15, 2007: WO/2007/019094 (3 worldwide citation)

The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by alt ...


58
GALARZA JOSE: Universal virus-like particle (vlp) influenza vaccines. TECHNOVAX, Pasternak Dahna S, August 25, 2011: WO/2011/102900 (3 worldwide citation)

Described herein are influenza virus-like particles (VLPs) that display one or more truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.


59
Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe: Adjuvanted influenza vaccines including cytokine-inducing agents. Novartis Vaccines And Diagnostics, Rappuoli Rino, O Hagan Derek, Del, Giudice Giuseppe, MARSHALL Cameron John, May 10, 2007: WO/2007/052056 (3 worldwide citation)

While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as ϝ-interferon response. Thus a vaccine comprises: (i) an influenza virus antigen; (ii) a ...


60
Scheffczik Hanno: Storage of influenza vaccines without refrigeration. Novartis Vaccines And Diagnostics & Co Kg, Scheffczik Hanno, MARSHALL Cameron John, October 4, 2007: WO/2007/110776 (3 worldwide citation)

Antigens from individual influenza virus strains are not refrigerated before being combined to make multivalent influenza virus vaccines. Moreover, influenza vaccines are not refrigerated between packaging and administration. Thus the need for refrigeration is minimized, and the cold-chain does not ...



Click the thumbnails below to visualize the patent trend.